Please use this identifier to cite or link to this item:
|Title:||Anti-HER2 Nanobody Labeled with 225Ac as a Potential Radiopharmaceutical for TRT|
|Authors:||PRUSZYNSKI Marek; LESZCZUK Edyta; RADCHENKO Valery; JOHN Kevin Dale; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; D’HUYVETTER Matthias; LAHOUTTE Tony|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 43 no. S1 p. S177|
|Type:||Articles in periodicals and books|
|Abstract:||Human epidermal growth factor receptor type 2 (HER2) is overexpressed in breast, ovarian, non-small cell lung, gastric and colon cancers, and portends poor prognosis. Intact mAbs are not always ideal vectors for radioimmunotherapy due to their slow pharmacokinetic and normal-tissue clearance. Nanobodies (Nbs) are single domain antibodies derived from Camelidae. Their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and normal tissues and ease of tumor penetration make them a very attractive platform for targeted radionuclide therapy (TRT). The goal of this study was to develop and characterize a potential molecular-targeted drug based on the anti-HER2-Nb labeled with 225Ac|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.